This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Cancio MI, Reiss UM, Nathwani AC, Davidoff AM, et al. Developments in the treatment of hemophilia B: focus on emerging gene therapy. Appl Clin Genet 2013; 6: 91-101.CancioMIReissUMNathwaniACDavidoffAMet alDevelopments in the treatment of hemophilia B: focus on emerging gene therapyAppl Clin Genet201369110110.2147/TACG.S31928Search in Google Scholar
Mannucci PM, Franchini M. Is haemophilia B less severe than haemophilia A? Haemophilia 2013; 19(4): 499-502.MannucciPMFranchiniMIs haemophilia B less severe than haemophilia A?Haemophilia201319449950210.1111/hae.12133Search in Google Scholar
Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19(1): e1-47.SrivastavaABrewerAKMauser-BunschotenEPKeyNSet alGuidelines for the management of hemophiliaHaemophilia2013191e14710.1111/j.1365-2516.2012.02909.xSearch in Google Scholar
Chalmers, A. Haemophilia A and B: disease differences and the use of prophylactic therapy. Available from http://www.hemophiliareport.com/pdf/HEMR0101.pdf (accessed 11 October 2017).ChalmersAHaemophilia A and B: disease differences and the use of prophylactic therapyAvailable fromhttp://www.hemophiliareport.com/pdf/HEMR0101.pdfaccessed 11 October2017Search in Google Scholar
Furlan R, Krishnan S, Vietri J. Patient and parent preferences for characteristics of prophylactic treatment in hemophilia. Patient Prefer Adherence 2015; 9: 1687-94.FurlanRKrishnanSVietriJPatient and parent preferences for characteristics of prophylactic treatment in hemophiliaPatient Prefer Adherence2015916879410.2147/PPA.S92520Search in Google Scholar
Pabinger-Fasching I. The story of a unique molecule in hemophilia A: recombinant single-chain factor VIII. Thromb Res 2016; 141 Suppl 3: S2-S4.Pabinger-FaschingI.The story of a unique molecule in hemophilia A: recombinant single-chain factor VIIIThromb Res2016141 Suppl3S2S410.1016/S0049-3848(16)30414-5Search in Google Scholar
Shima M, Lillicrap D, Kruse-Jarres R. Alternative therapies for the management of inhibitors. Haemophilia 2016; 22 Suppl 5: 36-41.ShimaMLillicrapDKruse-JarresRAlternative therapies for the management of inhibitorsHaemophilia201622 Suppl5364110.1111/hae.1300527405674Search in Google Scholar
Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med 2013; 4: 49-56.SaxenaKBarriers and perceived limitations to early treatment of hemophiliaJ Blood Med20134495610.2147/JBM.S43734366013323700376Search in Google Scholar
Cimino E, Linari S, Malerba M, Halimeh S, et al. Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries. Patient Prefer Adherence 2014; 8: 1713-20.CiminoELinariSMalerbaMHalimehSet alPatient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countriesPatient Prefer Adherence2014817132010.2147/PPA.S64709427029925525348Search in Google Scholar
Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7(4): 392-6.HackerMRGeraghtySManco-JohnsonMBarriers to compliance with prophylaxis therapy in haemophiliaHaemophilia2001743926Search in Google Scholar
Lindvall K, Colstrup L, Wollter IM, Klemenz G, et al. Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia. Haemophilia 2006; 12(1): 47-51.LindvallKColstrupLWollterIMKlemenzGet alCompliance with treatment and understanding of own disease in patients with severe and moderate haemophiliaHaemophilia2006121475110.1111/j.1365-2516.2006.01192.x16409174Search in Google Scholar
Vidovic N, Musso R, Klamroth R, Enriquez MM, et al. Postmarketing surveillance study of KOGENATE Bayer with Bio-Set in patients with haemophilia A: evaluation of patients' satisfaction after switch to the new reconstitution system. Haemophilia 2010; 16(1): 66-71.VidovicNMussoRKlamrothREnriquezMMet alPostmarketing surveillance study of KOGENATE Bayer with Bio-Set in patients with haemophilia A: evaluation of patients' satisfaction after switch to the new reconstitution systemHaemophilia2010161667110.1111/j.1365-2516.2009.02113.x19878338Search in Google Scholar
Khair K, Meerabeau L, Gibson F. Self-management and skills acquisition in boys with haemophilia. Health Expect 2015; 18(5): 1105-13.KhairKMeerabeauLGibsonFSelf-management and skills acquisition in boys with haemophiliaHealth Expect201518511051310.1111/hex.12083506084923711015Search in Google Scholar
Schrijvers LH, Beijlevelt-van der Zande M, Peters M, Schuurmans MJ, et al. Learning intravenous infusion in haemophilia: experience from the Netherlands. Haemophilia 2012; 18(4): 516-20.SchrijversLHBeijlevelt-vander Zande MPetersMSchuurmansMJet alLearning intravenous infusion in haemophilia: experience from the NetherlandsHaemophilia20121845162010.1111/j.1365-2516.2012.02752.x22292416Search in Google Scholar
Riva S, Nobili A, Djade CD, Mancuso ME, et al. Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia. Clin Interv Aging 2015; 10: 1141-6.RivaSNobiliADjadeCDMancusoMEet alCognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophiliaClin Interv Aging2015101141610.2147/CIA.S84749450167926185433Search in Google Scholar
European Medicines Agency. NovoEight: EPAR – product information. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002719/WC500157553.pdf Accessed 24 February 2017).European Medicines Agency. NovoEight: EPAR – product informationAvailable fromhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002719/WC500157553.pdfAccessed 24 February2017Search in Google Scholar
European Medicines Agency. NovoSeven: EPAR – product information. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000074/WC500030873.pdf (accessed 24 February 2017).European Medicines Agency. NovoSeven: EPAR – product informationAvailable fromhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000074/WC500030873.pdfaccessed 24 February2017Search in Google Scholar
Munn J, Khair K, Scott A, Shoemark R, et al. Patient and caregiver perceptions of a pre-filled diluent syringe (MixPro). J Haem Pract 2016; 3(1): doi: 10.17225/jhp00073.MunnJKhairKScottAShoemarkRet alPatient and caregiver perceptions of a pre-filled diluent syringe (MixPro)J Haem Pract20163110.17225/jhp00073Open DOISearch in Google Scholar
European Medicines Agency. Refixia: EPAR – product information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004178/WC500232816.pdf (accessed 11 October 2017).European Medicines Agency. Refixia: EPAR – product informationhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004178/WC500232816.pdfaccessed 11 October2017Search in Google Scholar
Makwana S, Basu B, Makasana Y, Dharamsi A. Prefilled syringes: an innovation in parenteral packaging. Int J Pharm Investig 2011; 1(4): 200-6.MakwanaSBasuBMakasanaYDharamsiAPrefilled syringes: an innovation in parenteral packagingInt J Pharm Investig201114200610.4103/2230-973X.93004346514423071944Search in Google Scholar
Zadbuke N, Shahi S, Gulecha B, Padalkar A, et al. Recent trends and future of pharmaceutical packaging technology. J Pharm Bioallied Sci 2013; 5(2): 98-110.ZadbukeNShahiSGulechaBPadalkarAet alRecent trends and future of pharmaceutical packaging technologyJ Pharm Bioallied Sci2013529811010.4103/0975-7406.111820369720023833515Search in Google Scholar
Khair K. Evaluating a self infusion device for children with haemophilia. Paediatr Nurs 2006; 18(10): 19-20.KhairKEvaluating a self infusion device for children with haemophiliaPaediatr Nurs20061810192010.7748/paed.18.10.19.s1617193913Search in Google Scholar
Fernandez-Arias I, Kim HK. Factor VIII delivery devices in haemophilia A. Barriers and drivers for treatment adherence. Farm Hosp 2016; 40(n06): 579-603.Fernandez-AriasIKimHKFactor VIII delivery devices in haemophilia A. Barriers and drivers for treatment adherenceFarm Hosp201640n06579603Search in Google Scholar
Musso R, Santoro R, Coppola A, Marcucci M, et al. Patient preference for needleless factor VIII reconstitution device: the Italian experience. Int J Gen Med 2010; 3: 203-8.MussoRSantoroRCoppolaAMarcucciMet alPatient preference for needleless factor VIII reconstitution device: the Italian experienceInt J Gen Med201032038Search in Google Scholar
